In the last trading session, 1.36 million Sarepta Therapeutics Inc (NASDAQ:SRPT) shares changed hands as the company’s beta touched 1.02. With the company’s per share price at $83.06 changed hands at -$0.09 or -0.11% during last session, the market valuation stood at $7.77B. SRPT’s last price was a discount, traded about -92.5% off its 52-week high of $159.89. The share price had its 52-week low at $55.25, which suggests the last value was 33.48% up since then. When we look at Sarepta Therapeutics Inc’s average trading volume, we note the 10-day average is 1.57 million shares, with the 3-month average coming to 1.49 million.
Analysts gave the Sarepta Therapeutics Inc (SRPT) stock a consensus recommendation rating of an Overweight, calculated at a mean rating of 1.63. If we narrow down to specifics, the data shows that 0 out of 20 analysts rate the stock as a Sell, with a further 2 assigning it an Overweight rating. Of the remaining, 5 recommended SRPT as a Hold, 13 felt it is a Buy and 0 rated the stock as Underweight. Sarepta Therapeutics Inc’s EPS for the current quarter is expected to be -$0.3.
Sarepta Therapeutics Inc (NASDAQ:SRPT) trade information
Instantly SRPT was in red as seen at the end of in last trading. With action 4.26%, the performance over the past five days has been green. The drop to weekly highs of 85.94 on Monday, 11/20/23 subtracted -0.11% to the stock’s daily price. The company’s shares are showing year-to-date downside of -35.90%, with the 5-day performance at 4.26% in the green. However, in the 30-day time frame, Sarepta Therapeutics Inc (NASDAQ:SRPT) is -25.31% down. Looking at the short shares, we see there were 4.45 million shares sold at short interest cover period of 2.24 days.
The consensus price target for the stock as assigned by Wall Street analysts is $139.22, meaning bulls need an upside of 40.34% from its current market value. According to analyst projections, SRPT’s forecast low is $80.00 with $224.00 as the target high. To hit the forecast high, the stock’s price needs a -169.68% plunge from its current level, while the stock would need to tank 3.68% for it to hit the projected low.
Sarepta Therapeutics Inc (SRPT) estimates and forecasts
Data shows that the Sarepta Therapeutics Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -44.28% over the past 6 months, a 6.23% in annual growth rate that is considerably lower than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for Sarepta Therapeutics Inc will rise 75.80%, while the growth in revenue is estimated to hit 95.20% for the next quarter. Year-over-year growth is forecast to reach 29.70% up from the last financial year.
Consensus estimates given by 14 financial analysts project the company’s revenue in the current quarter to hit an average of $364.86 million. 7 analysts are of the opinion that Sarepta Therapeutics Inc’s revenue for the quarter ending Mar 2024 will be $374.1 million. The company’s revenue for the corresponding quarters a year ago was $258.43 million and $253.5 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 41.20%. The estimates for the next quarter sales put growth at 47.60%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -56.35%. The 2023 estimates are for Sarepta Therapeutics Inc earnings to increase by 15.27%.
Sarepta Therapeutics Inc is expected to release its next quarterly earnings report on November 01.
Sarepta Therapeutics Inc (NASDAQ:SRPT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.25% of Sarepta Therapeutics Inc shares while 88.09% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 92.00%. There are 88.09% institutions holding the Sarepta Therapeutics Inc stock share, with Vanguard Group Inc the top institutional holder. As of Jun 29, 2023, the company held 9.69% of the shares, roughly 8.53 million SRPT shares worth $977.02 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 6.25% or 5.5 million shares worth $630.26 million as of Jun 29, 2023.
Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. With 2.78 million shares estimated at $317.87 million under it, the former controlled 3.15% of total outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held about 2.60% of the shares, roughly 2.28 million shares worth around $261.62 million.